Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV

Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer

Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.

AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion

AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed at $82.99 in the latest trading session, marking a -0.58% move from the prior day.

Sweta Killa headshot

Inflation to Pick Up in 2021: Bet on TIPS ETFs

The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.

Sweta Killa headshot

Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD

While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.

IPO Market Set to Thrive in December

IPO Market Set to Thrive in December

Mark Vickery headshot

DoorDash IPOs at $102, Vaccine Rally Cooling

DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.

Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy

Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.

Encouraging News on COVID-19 Vaccine

Encouraging News on COVID-19 Vaccine

Mark Vickery headshot

ADP Reports 307K New Jobs, Revisions Up

307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.

Kinjel Shah headshot

Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal

AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Is Merck & Co (MRK) a Good Value Investor Stock Right Now?

Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.

Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment

The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More

Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.

Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer

The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.

The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric

The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric

Kinjel Shah headshot

Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug

Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Merck & Honeywell

Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola Company (KO), Merck (MRK) and Honeywell International (HON).

Model N (MODN) Q4 Earnings Beat, Stock Down on Bleak View

Model N's (MODN) fourth-quarter fiscal 2020 results benefit from robust adoption of Revenue Cloud platform and strong sales execution. However, bleak guidance for fiscal 2021 remains a concern.

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study

Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.

Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss

Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.